Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 1236Neoplasms 1040Carcinoma, Non-Small-Cell Lung 861Prostatic Neoplasms 692Colorectal Neoplasms 614Lung Neoplasms 578Neoplasm Metastasis 439Multiple Myeloma 425Leukemia, Myeloid, Acute 401Pancreatic Neoplasms 376Ovarian Neoplasms 364Melanoma 320Carcinoma, Hepatocellular 288Recurrence 276Squamous Cell Carcinoma of Head and Neck 275Brain Neoplasms 266Glioblastoma 247Head and Neck Neoplasms 244Stomach Neoplasms 239Carcinoma, Renal Cell 228Precursor Cell Lymphoblastic Leukemia-Lymphoma 227Lymphoma 225Triple Negative Breast Neoplasms 219Hematologic Neoplasms 209Endometrial Neoplasms 209Urinary Bladder Neoplasms 202Lymphoma, Non-Hodgkin 197Uterine Cervical Neoplasms 194Sarcoma 190Glioma 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castration Resistant Prostate Cancer × 90 days × Clear all
NCT07093801 2026-05-15

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

Novartis

Recruiting
300 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT05219500 2026-04-03

TATCIST

Fusion Pharmaceuticals Inc.

Phase 2 Active not recruiting
115 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡